To investigate the effects of FLIPin compounds in combination with BV6 and CD95L/BV6 treatment, we utilized the colon cancer cell line HT29 and the pancreatic cancer cell line SUIT-020. The gene discussed is FASLG; the disease is malignant colon neoplasm.